Early Phase Development

Latest News

FDA Clears Anbogen’s Oral HDAC1/2/3 Inhibitor for Phase I/II Colorectal Trial
FDA Clears Anbogen’s Oral HDAC1/2/3 Inhibitor for Phase I/II Colorectal Trial

August 4th 2025

The Phase I/II trial will evaluate the safety and early efficacy of ABT-301 in combination with tislelizumab and bevacizumab in patients with colorectal cancer.

Credit: RAJCREATIONZS | stock.adobe.com
Phase I Trial Supports Development of Once-Yearly Lenacapavir as Long-Acting HIV PrEP Option

March 13th 2025

Credit: JYPIX | stock.adobe.com
Decentralized Phase I Trial Highlights Promise of Remote Data Collection to Improve Clinical Research

January 22nd 2025

Four-Steps to Accelerate Study Start-up Cycles
Four-Steps to Accelerate Study Start-up Cycles

March 5th 2024

How AI is Changing Early Drug Development
How AI is Changing Early Drug Development

February 22nd 2024

Video Interviews

More News

© 2025 MJH Life Sciences

All rights reserved.